Clinical trials: Vulval Cancer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Vulvar Cancer
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00504023
- Testing
- imiquimod, biopsy, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Uterine Cancer
Image-Guided Gynecologic Brachytherapy
Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation.
- Conditions
- Cervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva
- Trial name
- AMIGO (NCT01399658)
- Testing
- Image-guided brachytherapy, 3'-Deoxy-3'-18f-Fluorothymidine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib.
- Trial name
- NCT05949632
- Testing
- INCB099280, axitinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT00851643
- Testing
- Octavalent HPV with 15 mcg IMX / AAHS, Octavalent HPV with 30 mcg IMX / AAHS, Octavalent HPV with 60 mcg IMX / AAHS
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Cancer, Ovarian Cancer
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life
This study is being done to see if most patients are willing and able to report how they are feeling after surgery using the internet, and if this information can help doctors and nurses detect concerning symptoms after surgery.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Uterine Cancer
- Trial name
- NCT00870233
- Testing
- online platform WEBCORE
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Memorial Sloan Kettering Cancer Center